The 21st annual Biomed Israel Conference, attended by thousands of industry leaders from 45 countries, presented a juxtaposition of challenges and opportunities in the life sciences sector. There was a focus on the effects of the worldwide economic downturn and industry-specific concerns surrounding investment, drug pricing reform, and anti-trust regulator overreach. Amidst these challenges, however, there was palpable enthusiasm surrounding the innovative Israel life science ecosystem, the convergence of life sciences and technology, and remarkable advances in diagnostics, medical devices, biotech, and digital health. Our Freshfields Life Sciences team attended and engaged in discussions with clients and industry players. From these interactions, we observed the following themes: Key Takeaways from the 21st Annual Biomed Israel Conference, Ben Cohen (freshfields.us)

See all Member News